🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07104513
Active, not recruiting Observational

Efficacy and Influencing Factors of Repeated Low-level Red-light in Myopia

NCT07104513 · tracked via the Priya Life Science China tracker
Sponsor
Ruihua Wei
Phase
Observational
Started
2020-09-28
Last updated
2025-09-08

Condition(s) studied

Myopia

Investigational drug(s) / intervention(s)

Red Light

Red Light: use red light twice per day, both eyes. use red light for one year in The RLRL-1year Group. use red light for two year in The RLRL-2years Group. red light for three years in The RLRL-3years Group.red light for more than three years in The RLRL- more than 3years Group.

Study summary

To evaluate the long-term efficacy of repeated low-level red-light (RLRL) therapy in the prevention and control of myopia in children, and to analyze the key factors influencing its efficacy (such as individual differences and compliance), with the aim of providing evidence-based support for the optimization of clinical myopia prevention and control strategies.

Eligibility

Sex
ALL
Min age
5 Years
Max age
16 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Ages 5 to 16, gender unrestricted; 2. RLRL device usage duration of one year or more. Exclusion Criteria: * Children with obvious strabismus and amblyopia * With congenital eye disease, such as congenital cataract, congenital retinal disease * Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome) * Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.) * Refractive medium opacity (such as corneal disease, crystal opacity, etc.) * Bnormal intraocular pressure and clinical significance (IOP \<10 mmHg or IOP \>21mmHg or binocular IOP difference ≥5mmHg) * Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases * Optic nerve damage or congenital optic nerve dysfunction * Can not be regularly checked * The adjustment range is less than 8D or obvious near difficulties * Other reasons researchers think it is not suitable for inclusion in researchers

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Tianjin Medical University Eye Hospital Tianjin Tianjin Municipality
Tianjin Medical University Eye Hospital Tianjin China

More Ruihua Wei trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07104513 on ClinicalTrials.gov ↗ ← All trials in China